Lofenalac, it was necessary to increase total protein intake to over 5 glkglday. The amino acid imbalance which this caused was clearly related to the amino acid pattern of the feeds since both cows' milk and Lofenalac are low in cystine and taurine and relatively high in methionine and branched-chain amino acids. We suggest that the tyrosine content of Lofenalac should be increased by at least 20% to enable it to be used with whey based milks, thus avoiding an unnecessarily high protein intake and unbalanced amino acid intake.
The data presented here show that when our patient was growing at 20 g/kg/per day, which was necessary to achieve catch up growth, she required rather less than 90 mg/kg of phenylalanine and between 270 and 290 mg/kg of tyrosine. In infants without phenylketonuria, who are able to convert phenylalanine to tyrosine, the requirements for these two amino acids are best considered together. We conclude that a combined intake of at least 350 mg/kg, necessitating a protein intake of 3-5 to 4 g/kg from a whey adapted milk, is required for catch up growth in preterm infants. This estimate is in agreement with other studies.6 7 It has been pointed out that the volumes of milks such as Gold Cap SMA needed to achieve such protein intakes are needlessly high and could be avoided by using milks of higher protein content. We would add that the energy intake provided by large volumes of SMA is also high and may lead to reluctance to feed (and therefore prolonged tube feeding) and excessive fat deposition. 
Case history
The baby was admitted to hospital at 10 weeks of age having become jaundiced over a 24 hour period. She was passing dark urine and pale stools. She had been born after a normal delivery at 36 weeks' gestation, and weighed 2-5 kg. Apart from an episode of transient tachypnoea during the first 48 hours of life, the neonatal period was uneventful. Both parents were Caucasian, there was no history of contact with blood products or drug addiction, and the mother had remained well throughout her pregnancy. The baby had not been exposed to hepatitis nor had she received any blood transfusions.
On examination she was pale and slightly icteric. Investigations showed blood sugar 1-3 mmol/l (23.4 mg/100 ml); prothrombin time greater than 90 seconds (control 11-5 seconds); kaolin cephalin time greater than 3 minutes (control 42 seconds); haemoglobin 9-8 g/dl, reticulocytes 5%, fibrinogen nil detected; total serum bilirubin 268 mmol/l (15-7 mg/100 ml) (all unconjugated); alkaline phosphatase 170 KA units %, aspartate transaminase 113 IU/1, serum alanine transferase 198 IU/l; ammonia 105 ,umol/l (179 lAgI100 ml); the blood film showed spherocytes and acanthocytes. Subsequent management depended on clotting studies (see Figure) as well as continuous parenteral infusion of 10 to 20% dextrose to maintain a satisfactory blood sugar concentration. The baby's condition suddenly deteriorated 10 days after admission when she developed profound hypoglycaemia and progressed to grade IV hepatic failure. In spite of intensive support including lactulose, neomycin, and continued correction of anaemia, clotting disarray, and hypoglycaemia, she died. Consent for necropsy was not granted.
Screening antigen the specimen of blood taken from her, three months after delivery, was tested for hepatitis B core antibody IgM and was found to be negative. It was concluded that she was a long term carrier of hepatitis B surface antigen and was almost certainly hepatitis B e antibody positive at the time of delivery.
Methods
Tests for hepatitis B surface antigen by reverse passive haemagglutination and for hepatitis B e antigen and hepatitis B e antibody by enzyme immunoassay were done at the Public Health Laboratory, Fazakerley Hospital. The results of tests for hepatitis B e antigen and antibody were confirmed by radioimmunoassay at the Virus Reference Laboratory, Colindale, where the tests for hepatitis B core IgM antibody were also performed.
Discussion
Early in acute hepatitis B infection, hepatitis B surface antigen and hepatitis B e antigen appear in the serum. Hepatitis B core antibody appears during the acute phase of the illness followed by B e antibody which signals the cessation of viral replication. Antibody to surface antigen, which is associated with long term immunity, is detected after hepatitis B surface antigen has disappeared.
In certain high risk areas vertical transmission is believed to account for 40% of chronic carriers. Babies at particular risk are those born to hepatitis B surface antigen carrier mothers who are B e antigen positive-a measure of high infectivity. Of the babies who become infected, many develop chronic infection in adult life and this is implicated in the development of primary hepatocellular carcinoma.
The racial origin of the mother affects' the risk of transmission from mother to baby. Derso et al showed that there was a high carrier rate in Chinese babies born to mothers who were chronic carriers of hepatitis B surface antigen and no carriers were found among the European infants. Similarly, a study in two west London hospitals2 of maternal chronic carriers showed that eight of 18 infants with Chinese mothers became B surface antigen positive, but only six of 92 with mothers of other races were affected and that the presence of hepatitis B e antigen in the mother correlated with transmission to the child. Fetal heart monitoring during labour is now used in nearly all obstetric units to improve perinatal outcome. Several reports have described complications after the application of the scalp electrodes. 1-3
The whole spectrum of neonatal scalp changes associated with fetal monitoring, however, and their precise incidence have not as yet been described. We undertook a prospective study with daily examination of scalp changes in all newborn infants monitored during labour, and describe their incidence, clinical spectrum, and factors associated with severe complications.
Patients and methods
Study patients. All the infants delivered at the Beilinson Medical Center between 1 August, 1982 and 16 October, 1982 who had direct fetal heart rate monitoring during labour were included in the study. Of the total 660 live births during that period, 535 (81-1%) were monitored by scalp electrodes, and these infants comprised the study group. The 1513 OA fetal monitoring spiral electrodes (HewlettPackard Company USA) were used in our patients. 
